linjc16/ctgov huggingface dataset:
Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40

Study Overview
=================
Brief Summary
-----------------
Total intravenous anesthesia (TIVA) and inhalation anesthesia are both widely and safely used, and there are many clinical trials comparing these on various aspects of anesthesia. However, there have not been studies comparing the quality of recovery from the different methods of general anesthesia. In this study, the investigators compare the functional recovery after general anesthesia in TIVA and inhalation anesthesia with QoR-40 questionnaire.

Conditions
-----------------
Thyroid Operation Under General Anesthesia

Intervention / Treatment
-----------------
* Drug: desflurane group
* Drug: TIVA group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who are undergoing thyroid operation belong to ASA class 1 or 2 Exclusion Criteria: patients who are belongs to ASA class 3 or more, patients who have underlying complicated cardiovascular or psychological disease.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Desflurane group<br> | Drug: desflurane group<br>* anesthesia is maintained with desflurane and remifentanil (Desflurane group)<br>|
| Active Comparator: TIVA(total intravenous anesthesia) group<br> | Drug: TIVA group<br>* anesthesia is maintained with fresofol and remifentanil (TIVA group).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoR-40 score | QoR-40 score is going to be measured at preoperative period, 24 hours, and 48 hours later after surgery. | at 24 hours later after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
desflurane, total intravenous anesthesia, QoR-40
Misoprostol for Preventing Postpartum Hemorrhage

Study Overview
=================
Brief Summary
-----------------
This hospital-based, multicenter, randomized, placebo-controlled trial will assess the effects of misoprostol as part of active management of the third stage of labor on postpartum blood loss, complications, and side effects. Twelve hundred eligible women will receive routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo during or immediately after delivery. The primary outcome will be measured blood loss of =>500 mls within one hour after enrollment.

Official Title
-----------------
Misoprostol for Preventing Postpartum Hemorrhage

Conditions
-----------------
Postpartum Hemorrhage

Intervention / Treatment
-----------------
* Drug: misoprostol
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who have given birth to 1 or more live-born infants (para 1 or more) Vaginal delivery Exclusion Criteria: Refusal or inability to give informed consent Delivery regarded as abortion according to local gestational age limits Inability to take misoprostol sublingually Cesarean section Assisted vaginal delivery
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>placebo resembling misoprostol | Drug: placebo<br>* placebo resembling misoprosotl<br>|
| Experimental: 2<br>misoprostol | Drug: misoprostol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood loss =>500 mls within one hour after enrollment |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood loss =>1000 mls within one hour after enrollment |  |  | 
| Mean blood loss after enrollment |  |  | 
| Blood transfusion |  |  | 
| Hemoglobin level <8 g/dL 24 hours after delivery |  |  | 
| Maternal morbidity and mortality |  |  | 
| Side effects |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Misoprostol, Active management, Postpartum hemorrhage, Maternal morbidity, Anemia, Developing countries
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

Study Overview
=================
Brief Summary
-----------------
A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure

Detailed Description
-----------------
A two arm study (1 Active, 1 Active control) to compare the incidence, progression and severity of chronic renal allograft failure in at-risk patients who are converted from cyclosporine-based to tacrolimus-based immunosuppression to patients who remain on cyclosporine-based therapy

Official Title
-----------------
Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

Conditions
-----------------
Graft Rejection, Kidney Transplantation

Intervention / Treatment
-----------------
* Drug: tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been on cyclosporine-based immunosuppression regimen since the transplant Patient has at least one pre-defined risk factor for chronic allograft failure Exclusion Criteria: Patient is dialysis dependent Patient is recipient of a solid organ transplant other than the kidney

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: tacrolimus|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graft Survival |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient survival, Graft Loss |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment efficacy, Transplantation rejection, Kidney transplantation, Cyclosporine, tacrolimus
Office Hysteroscopy in Secondary Infertility After Cesarean Section

Study Overview
=================
Brief Summary
-----------------
All women with history of secondary infertility after caesarean section will be subjected to office hysteroscopy according to Royal college of obstetrics and gynecology guidelines to diagnose any subtle uterine abnormalities not detected by conventional means. Hysteroscopic examination will be done during the proliferation phase of the menstrual cycle. The hysteroscopic evaluation will include assessment of the cervical canal, intrauterine lesions, the endometrium and the uterotubal junction. . If hysteroscopy reveal a lesion, its type, size, location will be recorded. Transvaginal ultrasound will be done after the procedure to detect fluid in the douglas pouch to confirm patent tubes. Asses the uterine scar in details.

Official Title
-----------------
Role of Office Hysteroscopy in Cases of Secondary Infertility After Cesarean Section

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Procedure: office hysteroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with secondary infertility more than 2 years after cesarean section. Normal semen analysis Normal hysterosalpingography or laparoscopy within 1year Evidence of ovulation by transvaginal ultrasound Exclusion Criteria: • Cases with abnormal semen parameters. Patients with abnormal hysterosalpingography. Patients with anovulation. Hormonal disturbances; high level of prolactin, thyroid hormone disturbances, very high or very low follicular stimulating hormone and luteinizing hormone Patients known to be epileptic or with history of fits. Cardiac patients ( valve diseases, ischemic, arrhythmic)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of patients with abnormal scar findings in hysteroscopy | color of the scar and presence of niche | 1 year |
Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care

Study Overview
=================
Brief Summary
-----------------
Motivational interviewing and nutritional counseling for weight loss in primary care.

Detailed Description
-----------------
Overweight and obese participants will be recruited through local primary care offices. This study will test the effectiveness of motivational interviewing and nutritional counseling for weight loss. The treatment will be supplemented by internet support.

Official Title
-----------------
Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care

Conditions
-----------------
Overweight, Obesity

Intervention / Treatment
-----------------
* Behavioral: motivational interviewing and nutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 25-55 Daily access to internet and phone Recruited through local primary care offices. Age 18-65 Exclusion Criteria: Co-existing physical and/or psychiatric conditions that require more significant treatment (e.g., bipolar disorder, psychotic illnesses), and/or require more intensive treatment or hospitalization (e.g., suicidality, severe mood disorders) Meets criteria for current substance abuse/dependence Currently receiving psychiatric, psychological, behavioral, or pharmacologic treatment that is known to affect weight or eating Pregnant, breastfeeding, or plans to become pregnant during the treatment period Cardiac disease, including ischemic heart disease, congestive heart failure, conduction abnormalities, or a history of heart attack Serious neurologic illnesses (e.g., seizure history) or medical illnesses (e.g., impaired hepatic or renal function) Uncontrolled diabetes, thyroid conditions, or hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: motivational interviewing and nutrition<br>Motivational interviewing and nutritional counseling. | Behavioral: motivational interviewing and nutrition<br>* Motivational Interviewing and Nutritional Counseling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight in Pounds | Body weight in pounds measured 3 months after starting treatment. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight in Pounds | Body weight in pounds measured 6 months after starting treatment (3 month follow-up after active treatment ends). | 6 months |
Severe Head Injury Brain Analysis

Study Overview
=================
Brief Summary
-----------------
Safety and feasibility study investigating brain biopsy in severe head injury. When a patient undergoes craniotomy or ICP bolt insertion for trauma, a biopsy of brain tissue is taken. Blood, saliva, urine and faeces samples are also taken for 7 days following the brain biopsy. CSF is collected if a CSF drainage device is used.

Detailed Description
-----------------
A minor amendment was submitted to allow histological and immunohistochemical analysis of the samples.

Official Title
-----------------
Severe Head Injury Brain Analysis

Conditions
-----------------
Brain Injury Traumatic Severe

Intervention / Treatment
-----------------
* Procedure: Brain biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe traumatic brain injury - Exclusion Criteria: Coagulopathy -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trial participants<br>Patients with severe traumatic brain injury requiring craniotomy or ICP bolt insertion | Procedure: Brain biopsy<br>* Biopsy of brain tissue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of brain biopsy | Is it feasible to perform brain biopsy through ICP bolt or at time of craniotomy in TBI in order to obtain diagnostic tissue? | immediately after the intervention/procedure/surgery | 
| Safety of brain biopsy | Is it safe to perform brain biopsy through ICP bolt or at time of craniotomy in TBI? | immediately after the intervention/procedure/surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Classification of TBI | Classify TBI based on histopathological appearances | immediately after the intervention/procedure/surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Traumatic Brain Injury, Brain injury classification, Histology
Lung Transplantation for Pleuroparenchymal Fibroelastosis

Study Overview
=================
Brief Summary
-----------------
This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Official Title
-----------------
Lung Transplantation for Pleuroparenchymal Fibroelastosis : a French Multicentric Retrospective Study

Conditions
-----------------
Fibroelastosis

Intervention / Treatment
-----------------
* Procedure: Lung transplantation (single, lobar or bilateral lung transplantation)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung transplantation (any type) for pleuroparenchymal fibroelastosis Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs Exclusion Criteria: All other interstitial lung disease than pleuroparenchymal fibroelastosis Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| lung transplantation<br>Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis. | Procedure: Lung transplantation (single, lobar or bilateral lung transplantation)<br>* Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative mortality | Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality) | Any death up to 90 days after lung transplantation |
Consumer Health IT Tools: Impact on Experience, Access, and Outcomes for Patients With Complex Chronic Conditions

Study Overview
=================
Brief Summary
-----------------
Patient use of health IT tools to interact with healthcare providers and delivery systems, including exchanging secure messages with their medical providers and using other web-based tools, has great potential to increase patient access to care, change the way healthcare is delivered, and affect patient clinical outcomes. This study will examine the impact of implementation and use of consumer health IT tools on patient-reported access to care, utilization of medical care services, and clinical outcomes.

Official Title
-----------------
Consumer Health IT Tools: Impact on Patient Experience, Access, and Health Outcomes for Patients With Complex Chronic Conditions

Conditions
-----------------
Chronic Disease, Patient Outcome Assessment, Electronic Health Records

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic conditions Patient had at least 10-month membership in 2005 Exclusion Criteria: Patients less than age 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Ambulatory Care Sensitive Conditions (ACSC) Hospitalizations. Portal Users vs Those Who Are Not Portal Users | Number of ambulatory care sensitive conditions (ACSC) hospitalizations per 1000 patients per month among those who accessed the portal and those who did not access the portal. | Data from 2006-2007 | 
| Patient Self-report Survey Data | Patient-reported reasons for using the patient portal | March 2015-April 2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patient outcome assessment, electronic health records
The Protection Effect of Speeda® Rabies Vaccine for Human Use

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to achieve the post-marketing protective effect research of Speeda® rabies vaccine for human use from Chengda Bio.

Detailed Description
-----------------
When found the injury who is bitten by the animal to three-level, the investigators would enroll the participant after explaining the protection and making him signed the informed consent. The patient would inject rabies vaccine as follow the national regulation, meanwhile the investigators would get the blood samples to detect whether the man-killer carries the rabies virus.

Official Title
-----------------
Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level

Conditions
-----------------
Rabies Vaccine Allergy

Intervention / Treatment
-----------------
* Biological: rabies vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months before injured The man-killer could found and detect whether it carries the virus Exclusion Criteria: Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth Apply passive immunity preparation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rabies vaccine<br>When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die | Biological: rabies vaccine<br>* Injection on day 0、7、21<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observation of the subject after injured by the animals carrying the virus | Whether or when would the patients develop symptoms after injured by the animals carrying the virus | 2 years |